MAAIKE EVERTS, PHD
Executive Director
Translational Therapeutics Accelerator
Critical Path Institute

Presentation: 1:30–1:55 PM
Q&A: 1:55–2:00 PM

Title: “Academic Drug Discovery Support by the Critical Path Institute’s Translational Therapeutics Accelerator (TRxA)”

Abstract: The Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) is a global drug discovery and development program focused on supporting academic scientists in defining and funding optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients. TRxA’s nonprofit accelerator model accomplishes this by:

- Providing resources and hands-on guidance, with TRxA staff working closely with academic researchers to develop a comprehensive data package for potential drug candidates.
- Providing tactical and strategic drug discovery and development guidance, bringing diverse expertise to pivotal early-stage study design and implementation.
- Leveraging TRxA’s outsourcing model to facilitate involvement of contract research organizations (CROs) as necessary to perform critical experiments that cannot be conducted in the academic setting (e.g., key toxicology and other specialized studies). CROs may also be engaged for third-party validation of academic studies to develop the type of comprehensive and validated data package pharmaceutical companies require when making decisions about licensing opportunities.